12 known cases. View patent page →
MDL antitrust litigation in N.D. Cal. in which US 6,780,889 is listed among the patents at issue, along with US 10,213,400, US 10,864,181, and US 7,262,219, among others. The claims are antitrust, not patent infringement.
Lead Hatch-Waxman action asserting the '219 patent against Roxane; consolidated with several related Roxane actions. Claim construction issued 2012-09-14 and the case settled before trial.
Related Amneal action consolidated into the Jazz v. Amneal '219 patent litigation.
Related Par action consolidated into the Jazz v. Amneal '219 patent litigation.
Related Ranbaxy action listed on the '219 Google Patents litigation page and consolidated; settled pre-trial.
Related Watson action listed on the '219 Google Patents litigation page and consolidated; settled pre-trial.
Declaratory-judgment action listing the '219 patent among patents in the case, including 10,272,062; 10,736,866; 10,952,986; 7,851,506; and 8,731,963. Final disposition not confirmed.
Lumryz/FT218 litigation; trial record identifies the '219 patent as a Jazz patent. Actively litigated in 2023; final judgment not confirmed.
Antitrust action in which drugpatentwatch lists the '219 patent.
Antitrust action in which the '219 patent is listed.
Antitrust action brought by a Blue Cross/Blue Shield-related plaintiff; the '219 patent appears in the record.
Jazz Pharmaceuticals sued Ranbaxy Laboratories and Ranbaxy Inc. in a Hatch-Waxman ANDA patent infringement action over generic sodium oxybate referencing Xyrem. The complaint asserted multiple patents including U.S. Patent No. 8,461,203. The case was consolidated for all purposes into Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 13-391-ES-JAD, and administratively terminated.